Company summary & AIM Rule 26 information
Main Page Content
| Primary Country Listing | UK |
|---|---|
| Status | AIM |
| Index | FTSE AIM All Share |
| Sector | Alternative Energy |
| Activities | Investment company |
| EPIC | BIP |
| Overview from Annual Report | 31/12/2010 | 31/12/2009 |
|---|---|---|
| Ave. No. Employees (Excl. Directors) | 6 | 3 |
| Total Employee Cost | £0.181m | £0.07m |
| Gearing | -3.55% | -14.56% |
| ROCE | -5.94% | -6.99% |
| Latest Results - Interim | 30/06/2011 |
|---|---|
| Turnover (£m) | 0.04 |
| Pre-tax profit (£m) | -0.25 |
| EPS (undiluted and pre-exceptionals p) | -0.15 |
| Dividend (p) | 0 |
| Closing Share Price (p) | 4.5 | |
|---|---|---|
| Number of Shares in Issue (m) | 166.44 | |
| Market Capitalisation(£m) | 7.49 | |
The information below is being disclosed for the purposes of AIM Rule 26 and was last updated on 29 September 2010.
- Description of our business
- Directors
- Responsibilities of the members of the board of directors and details of committees
- Country of incorporation and main country of operation
- Biofutures International plc has not applied or agreed to have any of its securities (including its AIM securities) admitted or traded any other exchanges or trading platforms
- The number of AIM securities in issue is 151,060,000 and the percentage of AIM securities not in public hands is 22.40%. No shares are held in Treasury. The identity and percentage holdings of its significant shareholders are included in section Major shareholders
- Our most recent admission document together with any circulars or similar publications sent to shareholders within the past 12 months:
Circular to shareholders
- Our current constitutional documents:
Memorandum of Association
Biofutures Articles of Association (August 2008, 260 kB pdf) - There are no restrictions on the transfer of Biofutures International plc's AIM securities
- Notifications made in past 12 months
- Our most recent admission document:
-
Biofutures Admission Document (October 2006, 847 kB pdf)
-
- Details of our nominated adviser and other key advisers
